TABLE 1.
Plasmids used in this study
| Plasmid | Genotype | Reference or source |
|---|---|---|
| pDG1661 | 10 | |
| pDG1662 | 10 | |
| pDG784 | 9 | |
| pDG1515 | 9 | |
| pDG1726 | 9 | |
| pMS38 | Lab stock | |
| pLitmus28 | NEB | |
| pCG123 | pDG1662 + spoIIIAH | This study |
| pCG124 | pDG1662 + spoIIIAGH | This study |
| pCG125 | pDG1662 + spoIIIAFGH | This study |
| pCG126 | pDG1662 + spoIIIA′EFGH (bp 1010 to 1215 of spoIIIAE) | This study |
| pCG129 | pDG1661 + spoIIIAH | This study |
| pCG130 | pDG1661 + spoIIIAGH | This study |
| pCG131 | pDG1661 + spoIIIAFGH | This study |
| pCG132 | pDG1661 + spoIIIA′EFGH | This study |
| pCG134 | pDG1661 + P1spoIIIA | This study |
| pCG135 | pDG1661 + spoIIIAFGH (bp 1 to 42 of spoIIIAH) | This study |
| pCG136 | pDG1661 + spoIIIAFG (bp 1 to 42 of spoIIIAG) | This study |
| pCG137 | pDG1661 + spoIIIAF | This study |
| pCG138 | pDG1661 + spoIIIAF (200 bp 3′ of spoIIIAF deleted) | This study |
| pCG139 | pDG1661 + spoIIIAF (400 bp 3′ of spoIIIAF deleted) | This study |
| pCG140 | pDG1661 + spoIIIA′EFGH (bp 1 to 42 spoIIIAH) | This study |
| pCG141 | pDG1661 + spoIIIA′EFG (bp 1 to 42 spoIIIAG) | This study |
| pCG142 | pDG1661 + spoIIIA′EF | This study |
| pCG143 | pDG1661 + spoIIIA′EF (200 bp 3′ of spoIIIAF deleted)a | This study |
| pCG144 | pDG1661 + spoIIIA′EF (400 bp 3′ of spoIIIAF deleted) | This study |
| pCG145 | pDG1661 + spoIIIA′EF (600 bp 3′ of spoIIIAF deleted) | This study |
| pCG146 | pDG1661 + spoIIIA′E | This study |
| pCG149 | pDG1661 + spoIIIAF-lacZ (100 bp 5′ of spoIIIAF deleted) | This study |
| pCG150 | pDG1661 + spoIIIAF-lacZ (200 bp 5′ of spoIIIAF deleted)b | This study |
| pCG151 | pDG1661 + spoIIIAF-lacZ (300 bp 5′ of spoIIIAF deleted) | This study |
| pCG152 | pMS38 + spoIIIAF | This study |
| pCG153 | pMS38 + spoIIIAE | This study |
| pCG154 | pMS38 + spoIIIAD | This study |
| pCG155 | pMS38 + spoIIIAC | This study |
| pCG156 | pMS38 + spoIIIAB | This study |
| pCG162 | pDG1726 ΔgerR | This study |
| pCG163 | pDG784 ΔspoIIID | This study |
| pCG164 | pDG1726 ΔsigE | This study |
| pCG165 | pDG1515 ΔsigK | This study |
| pCG166 | pLitmus28 + spoIIIAFGH | This study |
| pCG167 | pDG1661 + PsspE (bp −165 to 14) | This study |
| pCG169 | pLitmus28 + spoIIIAFGH −30 C-to-T mutation | This study |
| pCG170 | pLitmus28 + spoIIIAFGH −12/−11 CA-to-GT mutation | This study |
| pCG179 | pDG1661 + P2spoIIIA −30 C-to-T mutation | This study |
| pCG180 | pDG1661 + P2spoIIIA −12/−11 CA-to-GT mutation | This study |
| pCG184 | pDG1661 + spoIIIAFGH −12/−11 CA-to-GT mutation | This study |
| pCG185 | pDG1662 + spoIIIAFGH −12/−11 CA-to-GT mutation | This study |
| pCG202 | pDG784 + spoIIIAFGH −12/−11 CA-to-GT mutation | This study |
a
This site was used as 3′ end for all remaining experiments.
b
The fragment of DNA from base 200 to base 415 of spoIIIAF is referred to as P2spoIIIA.